255.09MMarket Cap-2559P/E (TTM)
6.520High5.820Low48.32KVolume6.350Open6.110Pre Close298.48KTurnover0.23%Turnover RatioLossP/E (Static)42.59MShares9.97052wk High-3.30P/B127.98MFloat Cap2.70052wk Low--Dividend TTM21.37MShs Float28.265Historical High--Div YieldTTM11.46%Amplitude2.700Historical Low6.177Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
Update! Watching
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
Some Top Movers 🚨 3/8/2024
Buy side pressure still looking good
Sure hope some of Y’all caught this?
Update
GlobeNewswire· 7 mins ago
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- FoghornTherapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plan...
No comment yet